Skip to main content.
Menu

Pfizer Inc.

Picture of Martha Rosenberg

Pharma isn't going to deliver disappointing earnings to Wall Street just because it has few new drugs coming online and has failed at its very purpose. It is recycling old for brand new uses.

Picture of William Heisel

A new drug comes on the market that promises to improve people’s eyesight. “Clarivue! Make your cloudy days sunny again!”

Your editor says, “This Clarivue is like Viagra for eyeballs. It’s going to be flying off the shelves. Write up something for the Web in the next hour.”

Your next move should be to find out the NNT: . It will help you answer the most important question: How many people would need to take Clarivue in order for one person to actually see better?

Picture of William Heisel

Scott Reuben, a Massachusetts anesthesiologist, had landed a job as the chief of acute pain at Baystate Medical Center in Springfield. He also had published dozens of papers in academic journals touting the benefits of painkillers made by drug giants Pfizer and Merck.

Picture of William Heisel

Freelance journalist recently made an interesting comparison between embattled drug giant Wyeth and former insurance giant AIG. The latter famously handed out massive bonuses and planned lavish company retreats at a time when the company was receiving billions in federal bailout funds.

Picture of William Heisel

Career archivist Kim Klausner takes her roles as a historian and as a public health advocate equally seriously. As the Industry Documents Digital Libraries Manager for the University of California-San Francisco, she is in charge of the , a collection of thousands of records that shine a light on practices by Wyeth, Pfizer, Abbott and other Big Pharma companies.

Picture of William Heisel

writes the blog. He also runs , a medical education company that works with nonprofits and for-profits to create continuing medical education (CME) programs. As company-sponsored CME and ghostwriting by companies has come under fire, Sullivan has become an outspoken advocate for medical education firms.

Picture of William Heisel

When historians write the history of ghostwriting in U.S. medicine, they will mark Sept. 17, 2009 as pivotal.

Picture of William Heisel

Even in his infamy, Dr. Daniel Carlat, founder of , is popular with drug companies. Carlat was by to help promote a new drug.

Picture of Matthew Richmond

"It is not often that you are aware of the revolution right while you are in the midst of it. But we are," says , ombudsman at National Public Radio. And with those changes come a host of challenges for journalists working in a fast-changing climate, she recently told a group of broadcasters participating in Iso.in.ua Health Journalism Fellowships.

Pages

Announcements

Join us on March 22 for a daylong briefing on the U.S. Census. Participants will learn about the challenges facing counters, efforts to delegitimize the U.S. Census, how the climate of fear in immigrant communities might impede a good count, and discuss reporting and census data analysis strategies.  

What’s the difference between Medicare-for-all and Medicare-for-some? Are these realistic policy proposals, or political blips on the screen? Sign up here for our next Health Matters webinar!

If you're a journalist with big ideas who wants your work to matter, the Center for Health Journalism invites you to apply for the all-expenses-paid-- five days of stimulating discussions in Los Angeles about social and health safety net issues, reporting and engagement grants of $2,000-$12,000 and six months of expert mentoring.

CONNECT WITH THE COMMUNITY

www.bestseller-sales.com

препараты усиливающие потенцию для мужчин

www.adulttorrent.org/search/mistress tangent